Longeveron Inc Ordinary Shares - Class A LGVN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Longeveron to Participate in Three Longevity/Aging Investment Conferences
-
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
-
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
-
Longeveron Announces 1-for-10 Reverse Stock Split
-
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
-
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
-
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
-
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
Trading Information
- Previous Close Price
- $1.50
- Day Range
- $1.36–1.49
- 52-Week Range
- $1.36–12.30
- Bid/Ask
- $1.38 / $1.53
- Shares Outstanding
- 3.19M
- Market Cap
- $4.43M
- Volume/Avg
- 66,037 / 95,840
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.37
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 38
- Website
- https://www.longeveron.com
Valuation
|
Metric
|
LGVN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.66 |
Price/Sales | 4.37 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LGVN
|
|---|---|
Quick Ratio | 2.35 |
Current Ratio | 2.63 |
Interest Coverage | — |
Quick Ratio
LGVN
Profitability
|
Metric
|
LGVN
|
|---|---|
Return on Assets (Normalized) | −137.52% |
Return on Equity (Normalized) | −199.18% |
Return on Invested Capital (Normalized) | −184.75% |
Return on Assets
LGVN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|G>&l!< | LOCK|$T<tz | $129B | |||
| Moderna Inc
MRNA
| LOCK|xgV!@pr | LOCK|Zk# | $94B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|m@v><mR | LOCK|^^y># | $82B | |||
| argenx SE ADR
ARGX
| LOCK|?Cb@?&K | LOCK|G@! | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|zf&HBP | LOCK|B> | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^z?r?y | LOCK|!!ts | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|fc#!^n^< | LOCK|$P?#& | $27B | |||
| Incyte Corp
INCY
| LOCK|@Z<^&! | LOCK|hW | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Mz!^?t | LOCK|@@ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!!dX<# | LOCK|$> | $14B |
United States